PIK3CA, KRAS, and BRAF Mutations in Intraductal Papillary Mucinous Neoplasm/carcinoma (IPMN/C) of the Pancreas

Overview

Journal Langenbecks Arch Surg

Specialty General Surgery

Date 2008 Mar 18

PMID 18343945

Citations 38

Authors

Frank Schonleben

Wanglong Qiu

Helen E Remotti

Werner Hohenberger

Gloria H Su

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Recent studies have reported high frequencies of somatic mutations in the phosphoinositide-3-kinase catalytic-alpha (PIK3CA) gene in various human tumors. Three hot-spot mutations in the exons 9 and 20 have been proven to activate the Akt signalling pathway. The Raf/MEK/ERK (mitogen-activated protein kinase) signal transduction is an important mediator of a number of cellular fates including growth, proliferation, and survival. The BRAF gene is activated by oncogenic RAS, leading to cooperative effects in cells responding to growth factor signals. Here we evaluate the mutational status of PIK3CA, KRAS, and BRAF in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMNC) of the pancreas.

Materials And Methods: Exons 1, 4, 5, 6, 7, 9, 12, 18, and 20 of PIK3CA, exons 1 of KRAS, and exons 5, 11, and 15 of BRAF were analyzed in 36 IPMN/IPMC and two mucinous cystadenoma specimens by direct genomic DNA sequencing.

Results: We identified four somatic missense mutations of PIK3CA within the 36 IPMN/IPMC specimens (11%). One of the four mutations, H1047R, has been previously reported to be a hot-spot mutation. Furthermore, we found 17 (47%) KRAS mutations in exon 1 and one missense mutation (2.7%) in exon 15 of BRAF.

Conclusion: This data is the first report of PIK3CA mutation in pancreatic cancer and it appears to be the first oncogene to be mutated in IPMN/IPMC but not in conventional ductal adenocarcinoma of the pancreas. Our data provide evidence that PIK3CA and BRAF contribute to the tumorigenesis of IPMN/IPMC, but at a lower frequency than KRAS.

Citing Articles

Next-Generation Sequencing: An Advanced Diagnostic Tool for Detection of Pancreatic Disease/Disorder.

Biswas S, Afrose S, Mita M, Hasan M, Shimu M, Zaman S JGH Open. 2024; 8(11):e70061.

PMID: 39605899 PMC: 11599877. DOI: 10.1002/jgh3.70061.

An Overview for Clinicians on Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas.

Moris D, Liapis I, Gupta P, Ziogas I, Karachaliou G, Dimitrokallis N Cancers (Basel). 2024; 16(22).

PMID: 39594780 PMC: 11593033. DOI: 10.3390/cancers16223825.

Oncogenic GNAS Uses PKA-Dependent and Independent Mechanisms to Induce Cell Proliferation in Human Pancreatic Ductal and Acinar Organoids.

Desai R, Huang L, Gonzalez R, Muthuswamy S Mol Cancer Res. 2024; 22(5):440-451.

PMID: 38319286 PMC: 10906748. DOI: 10.1158/1541-7786.MCR-23-0199.

Molecular analysis with pancreaseq® in evaluation and management of pancreatic cysts: A cohort of 28 patients.

Deniz Ardor G, Hanna H, Ozalp B, Nassar A Cytojournal. 2023; 20:23.

PMID: 37681071 PMC: 10481854. DOI: 10.25259/Cytojournal_28_2023.

Construction of a metabolism-related gene prognostic model to predict survival of pancreatic cancer patients.

Huang H, Zhou S, Zhao X, Wang S, Yu H, Lan L Heliyon. 2023; 9(1):e12378.

PMID: 36820187 PMC: 9938416. DOI: 10.1016/j.heliyon.2022.e12378.

References

Su G, Hruban R, Bansal R, Bova G, Tang D, Shekher M . Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol. 1999; 154(6):1835-40. PMC: 1866632. DOI: 10.1016/S0002-9440(10)65440-5. View

Rul W, Zugasti O, Roux P, Peyssonnaux C, Eychene A, Franke T . Activation of ERK, controlled by Rac1 and Cdc42 via Akt, is required for anoikis. Ann N Y Acad Sci. 2002; 973:145-8. DOI: 10.1111/j.1749-6632.2002.tb04624.x. View

Calhoun E, Jones J, Ashfaq R, Adsay V, Baker S, Valentine V . BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol. 2003; 163(4):1255-60. PMC: 1868306. DOI: 10.1016/S0002-9440(10)63485-2. View

Fujii H, Inagaki M, Kasai S, Miyokawa N, Tokusashi Y, Gabrielson E . Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol. 1997; 151(5):1447-54. PMC: 1858094. View

Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, Tannapfel A . Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene. 2003; 22(30):4757-9. DOI: 10.1038/sj.onc.1206705. View

Motojima K, Urano T, Nagata Y, Shiku H, Tsurifune T, Kanematsu T . Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. Ann Surg. 1993; 217(2):138-43. PMC: 1242752. DOI: 10.1097/00000658-199302000-00007. View

Aguirre-Ghiso J, Estrada Y, Liu D, Ossowski L . ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 2003; 63(7):1684-95. View

Whitman M, Downes C, Keeler M, Keller T, Cantley L . Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature. 1988; 332(6165):644-6. DOI: 10.1038/332644a0. View

Yamao K, Ohashi K, Nakamura T, Suzuki T, Shimizu Y, Nakamura Y . The prognosis of intraductal papillary mucinous tumors of the pancreas. Hepatogastroenterology. 2000; 47(34):1129-34. View

10.

Sato N, Ueki T, Fukushima N, Iacobuzio-Donahue C, Yeo C, Cameron J . Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology. 2002; 123(1):365-72. DOI: 10.1053/gast.2002.34160. View

11.

Smalley K . A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int J Cancer. 2003; 104(5):527-32. DOI: 10.1002/ijc.10978. View

12.

Dong J, Phelps R, Qiao R, Yao S, Benard O, Ronai Z . BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003; 63(14):3883-5. View

13.

Iacobuzio-Donahue C, Klimstra D, Adsay N, Wilentz R, Argani P, Sohn T . Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol. 2000; 157(3):755-61. PMC: 1885701. DOI: 10.1016/S0002-9440(10)64589-0. View

14.

Benes C, Wu N, Elia A, Dharia T, Cantley L, Soltoff S . The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell. 2005; 121(2):271-80. DOI: 10.1016/j.cell.2005.02.019. View

15.

Wang Y, Helland A, Holm R, Kristensen G, Borresen-Dale A . PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat. 2005; 25(3):322. DOI: 10.1002/humu.9316. View

16.

Sahin F, Maitra A, Argani P, Sato N, Maehara N, Montgomery E . Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol. 2003; 16(7):686-91. DOI: 10.1097/01.MP.0000075645.97329.86. View

17.

Zgraggen K, Rivera J, Compton C, Pins M, Werner J, Fernandez-Del Castillo C . Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg. 1997; 226(4):491-8; discussion 498-500. PMC: 1191067. DOI: 10.1097/00000658-199710000-00010. View

18.

Campbell I, Russell S, Choong D, Montgomery K, Ciavarella M, Hooi C . Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004; 64(21):7678-81. DOI: 10.1158/0008-5472.CAN-04-2933. View

19.

Satoh K, Shimosegawa T, Moriizumi S, Koizumi M, Toyota T . K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Pancreas. 1996; 12(4):362-8. DOI: 10.1097/00006676-199605000-00007. View

20.

DAngelica M, Brennan M, Suriawinata A, Klimstra D, Conlon K . Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg. 2004; 239(3):400-8. PMC: 1356240. DOI: 10.1097/01.sla.0000114132.47816.dd. View